Publications by authors named "Kristen Lo Sicco"

61 Publications

A new eruption of bullous pemphigoid within psoriatic plaques following cyclosporine withdrawal.

JAAD Case Rep 2021 Feb 10;8:23-25. Epub 2020 Dec 10.

Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2020.12.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806540PMC
February 2021

Chronic Hydroxychloroquine Therapy and COVID-19 Outcomes: A Retrospective Case-Control Analysis.

J Am Acad Dermatol 2021 Jan 10. Epub 2021 Jan 10.

The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, NY, USA. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.10.098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797175PMC
January 2021

Laboratory Testing in Telogen Effluvium.

J Drugs Dermatol 2021 Jan;20(1):110-111

Telogen effluvium (TE) – a common cause of non- scarring hair loss – is managed with varying clinical protocols given the paucity of evidence-based practices.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.36849/JDD.2021.5771DOI Listing
January 2021

Prediction of therapeutic outcomes of female pattern hair loss patients based on clinical features with application of artificial intelligence.

J Am Acad Dermatol 2020 Dec 25. Epub 2020 Dec 25.

Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.12.035DOI Listing
December 2020

CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health.

J Am Acad Dermatol 2020 Nov 28. Epub 2020 Nov 28.

Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, New York; Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, New York; Division of Hematology, New York University School of Medicine, New York, New York; Division of Vascular Surgery, Department of Surgery, New York University School of Medicine, New York, New York.

Background: Psoriasis is associated with increased cardiovascular risk that is not captured by traditional proinflammatory biomarkers.

Objective: To investigate the relationship between Psoriasis Area and Severity Index, circulating proinflammatory biomarkers, and vascular health in psoriasis.

Methods: In patients with psoriasis and in age and sex-matched controls, 273 proteins were analyzed with the Proseek Multiplex Cardiovascular disease reagents kit and Inflammatory reagents kit (Olink Bioscience), whereas vascular endothelial inflammation and health were measured via direct transcriptomic analysis of brachial vein endothelial cells.

Results: In psoriasis, chemokine ligand 20 (CCL20), interleukin (IL) 6, and IL-17A were the top 3 circulating proinflammatory cytokines. Vascular endothelial inflammation correlated with CCL20 (r = 0.55; P < .001) and less so with IL-6 (r = 0.36; P = .04) and IL-17A (r = 0.29; P = .12). After adjustment for potential confounders, the association between CCL20 and vascular endothelial inflammation remained significant (β = 1.71; P = .02). In nested models, CCL20 added value (χ = 79.22; P < .001) to a model already incorporating the Psoriasis Area and Severity Index, Framingham risk, high-sensitivity C-reactive protein, Il-17A, and IL-6 (χ = 48.18; P < .001) in predicting vascular endothelial inflammation.

Limitations: Our study was observational and did not allow for causal inference in the relationship between CCL20 and cardiovascular risk.

Conclusion: We demonstrate that CCL20 expression has a strong association with vascular endothelial inflammation, reflects systemic inflammation, and may serve as a potential biomarker of impaired vascular health in psoriasis.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.10.094DOI Listing
November 2020

Necrolytic acral erythema in a patient with sarcoidosis.

JAAD Case Rep 2020 Nov 6;6(11):1162-1164. Epub 2020 May 6.

The Ronald O. Perelman Department of Dermatology, New York University Langone Health, New York, New York.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2020.04.035DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588658PMC
November 2020

Platelet-rich plasma, a promising adjunctive treatment for vitiligo: A case report.

JAAD Case Rep 2020 Dec 8;6(12):1320-1322. Epub 2020 Oct 8.

The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2020.09.021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543927PMC
December 2020

Acrofacial purpura and necrotic ulcerations in COVID-19: a case series from New York City.

Int J Dermatol 2020 Nov 23;59(11):1419-1422. Epub 2020 Sep 23.

The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, NY, USA.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.15181DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537226PMC
November 2020

Pruritus and Tense Bullae After Discontinuation of Pembrolizumab in a Patient With Renal Cell Carcinoma.

JAMA 2020 Sep 14. Epub 2020 Sep 14.

The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2020.10159DOI Listing
September 2020

Clinical Characteristics of Lupus Erythematosus Panniculitis/Profundus: A Retrospective Review of 61 Patients.

JAMA Dermatol 2020 Sep 2. Epub 2020 Sep 2.

The Ronald O. Perelman Department of Dermatology, New York University Langone Medical Center, New York, New York.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2020.2797DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489404PMC
September 2020

Response to "Variables affecting the potential efficacy of platelet-rich plasma in dermatology".

J Am Acad Dermatol 2021 Jan 26;84(1):e49. Epub 2020 Aug 26.

The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.08.081DOI Listing
January 2021

Response to: "Minimum requirements for reporting clinical trials evaluating the therapeutic potential of platelet-rich plasma".

J Am Acad Dermatol 2021 Jan 26;84(1):e45. Epub 2020 Aug 26.

The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.08.079DOI Listing
January 2021

Response to "Patient preference for cellulitis treatment: at-home care is preferred to hospital-based treatment".

J Am Acad Dermatol 2020 Aug 7. Epub 2020 Aug 7.

The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, NY.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.07.120DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413198PMC
August 2020

The Utility of Platelet-Rich Plasma for the Treatment of Alopecia.

J Drugs Dermatol 2020 Jul;19(7):736-741

Importance: Platelet-rich plasma (PRP) is a novel therapy for alopecia. Although the use of PRP remains under investigation, medical practitioners administer PRP for hair regrowth without quantitative evidence of clinical results. Objective: Systematically review literature regarding PRP for alopecia. Evidence Review: PRISMA guidelines were utilized to search the PubMed database in May 2019 with search terms "platelet rich plasma" and "hair", "hair loss", or "alopecia". Manuscripts were included if they were written in English and described PRP treatment in human subjects with alopecia. Findings: Sixty-one articles discussed the use of PRP as monotherapy, or in combination with other medical modalities, for the treatment of androgenetic alopecia (AGA), alopecia areata (AA), and cicatricial alopecia, ranging from level Ib to IV evidence. PRP results in significant increase in hair density and hair shaft width in AGA patients, with high rates of patient satisfaction and minimal adverse events. Data heterogeneity and limited number of well-designed, large-scale clinical trials were limitations of this review. Conclusions and Relevance: Preliminary results regarding the use of PRP for AGA, AA, and cicatricial alopecias are promising. Physicians should be aware that current studies often report qualitative, rather than quantitative, clinical outcomes and should counsel patients regarding PRP treatment efficacy accordingly. J Drugs Dermatol. 2020;19(7): doi:10.36849/JDD.2020.5192.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.36849/JDD.2020.5192DOI Listing
July 2020

Evaluation of platelet-rich plasma as a treatment for androgenetic alopecia: A randomized controlled trial.

J Am Acad Dermatol 2020 Nov 9;83(5):1298-1303. Epub 2020 Jul 9.

Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York.

Background: Platelet-rich plasma (PRP) shows promise as an androgenetic alopecia (AGA) treatment.

Objective: To conduct a randomized placebo-controlled split-scalp study to investigate the effects of PRP on hair regrowth and thickness.

Methods: Two 7.6-cm × 7.6-cm squares were tattooed on the scalps of 35 study participants with AGA. Areas were randomly assigned to intradermal injection with PRP or saline. Participants received 3 monthly treatment sessions with evaluation 3 months after the final treatment.

Results: Hair density in the PRP-treated area was significantly increased compared with baseline at all visits. At the final assessment, hair density in PRP-treated areas increased from 151 ± 39.82 hairs/cm at baseline to 170.96 ± 37.14 hairs/cm, a mean increase of approximately 20 hairs/cm (P < .05). However, hair density in placebo-treated areas also increased from 151.04 ± 41.99 hairs/cm to 166.72 ± 37.13 hairs/cm (P < .05). There was no significant difference in hair density change between the 2 groups (P > .05). No serious adverse events were reported.

Limitations: Possible PRP diffusion due to split-scalp study design as well as microinjections causing microinjury to both sides.

Conclusion: PRP may have benefit in increasing hair density.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.07.006DOI Listing
November 2020

Dermatologists' Role in the Diagnosis and Management of Coronavirus Disease 2019 Coagulopathy.

Am J Clin Dermatol 2020 08;21(4):599-600

The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, 240 E 38th St 14th floor, New York, NY, 10016, USA.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-020-00540-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343906PMC
August 2020

Use of platelet-rich plasma in lichen planopilaris and its variants: A retrospective case series demonstrating treatment tolerability without koebnerization.

J Am Acad Dermatol 2020 Nov 15;83(5):1506-1509. Epub 2020 Jun 15.

The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.06.026DOI Listing
November 2020

Dupilumab for allergic contact dermatitis and implications for patch testing: Irreconcilable differences.

J Am Acad Dermatol 2020 09 14;83(3):e215-e216. Epub 2020 May 14.

Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.05.036DOI Listing
September 2020

Evidenced-based guidelines for tuberculosis screening before biologic treatment initiation.

J Am Acad Dermatol 2020 07 25;83(1):e25-e26. Epub 2020 Mar 25.

The Ronald O. Perelman Department of Dermatology, New York University Langone Health, New York, New York.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.02.084DOI Listing
July 2020

Response of Lichen Planopilaris to Pioglitazone Hydrochloride

J Drugs Dermatol 2019 Dec;18(12):1276-1279

Lichen planopilaris (LPP) is a cicatricial alopecia that often causes permanent hair loss. Pioglitazone, a peroxisome proliferator activated receptor-gamma (PPAR- γ) agonist, has demonstrated immunomodulatory properties that may offer an effective treatment modality. This retrospective analysis describes 23 patients with LPP treated with adjunctive pioglitazone. Most (18/25) demonstrated significant reduction in patient-reported symptoms and clinical signs of inflammation. No adverse effects were reported. J Drugs Dermatol. 2019;18(12):1276-1279.
View Article and Find Full Text PDF

Download full-text PDF

Source
December 2019

Intravenous Immunoglobulin for Refractory Eosinophilic Fasciitis: A Retrospective Analysis from 3 Tertiary Care Centers.

J Am Acad Dermatol 2019 Dec 14. Epub 2019 Dec 14.

The Ronald O. Perelman Department of Dermatology, New York University Langone Medical Center, New York, NY. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.12.022DOI Listing
December 2019

Case report of discoid lupus erythematosus in association with electronic cigarette use.

JAAD Case Rep 2019 Dec 13;5(12):1030-1032. Epub 2019 Nov 13.

The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2019.05.027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864197PMC
December 2019

Eosinophilic Fasciitis With Concomitant Morphea Profunda Treated With Intravenous Immunoglobulin.

J Clin Rheumatol 2019 Oct 29. Epub 2019 Oct 29.

The Ronald O. Perelman Department of Dermatology New York University School of Medicine New York, NY

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000001158DOI Listing
October 2019

Chemotherapy-induced alopecia-A potentially preventable side effect with scalp cooling.

J Am Acad Dermatol 2020 02 1;82(2):e57-e59. Epub 2019 Oct 1.

Department of Dermatology, New York University, New York.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.09.059DOI Listing
February 2020

Paradoxical Mucositis Associated With Anti-Tumor Necrosis Factor Therapy.

J Clin Rheumatol 2020 Dec;26(8):e309-e310

Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, NY.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000001163DOI Listing
December 2020

Cutaneous T Cell Lymphoma: A Difficult Diagnosis Demystified.

Dermatol Clin 2019 Oct;37(4):455-469

The Ronald O. Perelman Department of Dermatology, 240 East 38th Street, 11th Floor, New York, New York 10016, USA; New York Harbor VA Healthcare System, Dermatology Residency Training Program. Electronic address:

Cutaneous T cell lymphoma (CTCL) represents a heterogeneous group of extranodal non-Hodgkin lymphomas in which monoclonal T lymphocytes infiltrate the skin. The mechanism of CTCL development is not fully understood, but likely involves dysregulation of various genes and signaling pathways. A variety of treatment modalities are available, and although they can induce remission in most patients, the disease may recur after treatment cessation. Owing to relatively low incidence and significant chronicity of disease, and the high morbidity of some therapeutic regimens, further clinical trials are warranted to better define the ideal treatment option for each subtype of CTCL.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.det.2019.05.007DOI Listing
October 2019

Morphea in a patient undergoing treatment with ustekinumab.

JAAD Case Rep 2019 Jul 26;5(7):590-592. Epub 2019 Jun 26.

The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2019.05.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610639PMC
July 2019

Case report of novel combination of anthralin and calcipotriene leading to trichologic response in alopecia areata.

JAAD Case Rep 2019 Mar 1;5(3):258-260. Epub 2019 Mar 1.

The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2019.01.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403115PMC
March 2019